Chemomab Therapeutics Ltd - ADR Stock

$1.05

1.87% yesterday

Nasdaq, Apr 04, 10:00 pm CET

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Chemomab Therapeutics Ltd - ADR Stock price

$1.05

-10.15 90.63% 5Y

Nasdaq, Closing price Fri, Apr 04 2025

-0.02 1.87%

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$19.80m
Enterprise Value	$5.78m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	1.21
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.81m
Cash position	$14.34m
EPS (TTM) EPS	$-0.89
P/E forward	negative
Short interest	1.44%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Chemomab Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Chemomab Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.03 0.03	57% 57% -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.47 3.47	50% 50% -
- Research and Development Expense	11 11	38% 38% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-15 -15	41% 41% -
Net Profit	-14 -14	42% 42% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Chemomab Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

9 days ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.

Neutral

GlobeNewsWire

●

30 days ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation th...

Neutral

GlobeNewsWire

●

about one month ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval

More Chemomab Therapeutics Ltd - ADR News

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Head office	United States
CEO	Adi Mor
Founded	2011
Website	www.chemomab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now